VLA Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Valneva SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.40 |
52 Week High | €6.05 |
52 Week Low | €2.23 |
Beta | 1.02 |
11 Month Change | -5.00% |
3 Month Change | -31.97% |
1 Year Change | -58.60% |
33 Year Change | -88.58% |
5 Year Change | -3.97% |
Change since IPO | -78.14% |
Recent News & Updates
Recent updates
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Nov 10Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Sep 19Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 17Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 10Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts
Jan 06Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?
Dec 13Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?
Aug 10Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry
May 12Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt
Jan 30Shareholder Returns
VLA | FR Biotechs | FR Market | |
---|---|---|---|
7D | -7.3% | -4.0% | -2.6% |
1Y | -58.6% | -23.8% | -3.4% |
Return vs Industry: VLA underperformed the French Biotechs industry which returned -23.8% over the past year.
Return vs Market: VLA underperformed the French Market which returned -3.4% over the past year.
Price Volatility
VLA volatility | |
---|---|
VLA Average Weekly Movement | 7.3% |
Biotechs Industry Average Movement | 6.9% |
Market Average Movement | 4.4% |
10% most volatile stocks in FR Market | 9.5% |
10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: VLA's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: VLA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
VLA fundamental statistics | |
---|---|
Market cap | €389.04m |
Earnings (TTM) | -€7.42m |
Revenue (TTM) | €158.54m |
2.5x
P/S Ratio-52.4x
P/E RatioIs VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VLA income statement (TTM) | |
---|---|
Revenue | €158.54m |
Cost of Revenue | €163.61m |
Gross Profit | -€5.08m |
Other Expenses | €2.34m |
Earnings | -€7.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
Earnings per share (EPS) | -0.046 |
Gross Margin | -3.20% |
Net Profit Margin | -4.68% |
Debt/Equity Ratio | 79.4% |
How did VLA perform over the long term?
See historical performance and comparison